NV Medtech
Reno, US · Founded 2021 · Delaware corporation
NVMedtech develops the TUBE flow diverter, a minimally invasive implant that treats brain aneurysms by promoting rapid aneurysm occlusion and tissue growth across the aneurysm neck. The device is a medical implant for neurovascular intervention, offering high surface coverage, high pore density, and a heparin surface coating.
Founders & leadership
GB
JE
Jeffrey EstesExecutive
Board
CP
Christopher P. MartinBoard director
WK
William KellyBoard director
Reported raises · per SEC filings
Form D private placements$20.9M disclosed across 1 round · 2026
▶$20.9MraisedJun 2026 · 4 investors · Other Health CareRule 506(b)
▶$20.9MraisedJun 2026 · 4 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
- Christopher P. MartinDirector
- William KellyDirector
- George B. WallaceExecutive Officer, Director
- Jeffrey EstesExecutive Officer
- Offering amount
- $20.9M
- Amount sold
- $20.9M
- First sale
- May 2026
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does NV Medtech do?
- NVMedtech develops the TUBE flow diverter, a minimally invasive implant that treats brain aneurysms by promoting rapid aneurysm occlusion and tissue growth across the aneurysm neck. The device is a medical implant for neurovascular intervention, offering high surface coverage, high pore density, and a heparin surface coating.
- How much funding has NV Medtech raised?
- NV Medtech has disclosed $20.9M raised across 1 round.
- Where is NV Medtech headquartered?
- NV Medtech is headquartered in Reno, US.